Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1006 to 1020 of 1455 results for do not do recommendations

  1. Total distal radioulnar joint replacement for symptomatic joint instability or arthritis (IPG595)

    Evidence-based recommendations on total distal radioulnar joint replacement for symptomatic joint instability or arthritis in adults. This involves removing the wrist end of the ulna and replacing it with a metal prosthesis that also attaches to the wrist end of the radius.

  2. YAG laser vitreolysis for symptomatic vitreous floaters (IPG741)

    Evidence-based recommendations on YAG laser vitreolysis for symptomatic vitreous floaters. This involves a special type of laser (YAG) firing short pulses of energy into the floaters, to break them up (vitreolysis) and reduce sight disturbances.

  3. Transcutaneous electrical neuromuscular stimulation for urinary incontinence (IPG735)

    Evidence-based recommendations on transcutaneous electrical neuromuscular stimulation for urinary incontinence in adults. This involves stimulating nerves and muscles in the pelvic floor to strengthen the muscles and reduce urine leaks.

  4. What interventions are effective and cost effective at raising awareness of the health risks of damp and mould in the home?

    Recommendation ID NG149/5 Question What interventions are effective and cost effective at raising awareness of the health risks of damp

  5. Ixekizumab for treating axial spondyloarthritis (TA718)

    Evidence-based recommendations on ixekizumab (Taltz) for treating axial spondyloarthritis in adults.

  6. Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis (TA988)

    Evidence-based recommendations on ivacaftor–tezacaftor–elexacaftor (Kaftrio) plus ivacaftor (Kalydeco), tezacaftor–ivacaftor (Symkevi) plus ivacaftor, and lumacaftor–ivacaftor (Orkambi) for treating cystic fibrosis.

  7. Regorafenib for previously treated advanced hepatocellular carcinoma (TA555)

    Evidence-based recommendations on regorafenib (Stivarga) for treating advanced hepatocellular carcinoma in adults who have had sorafenib.

  8. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies (TA704)

    Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer in adults after 2 or more anti-HER2 therapies.

  9. Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea (TA776)

    Evidence-based recommendations on pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea in adults.

  10. Digitally enabled therapies for adults with depression: early value assessment (HTE8)

    Early value assessment (EVA) guidance on digitally enabled therapies for adults with depression....

  11. Management of emergency department patients during the COVID-19 pandemic (Word)

    and those caring for them should be provided with information on what to do and who to contact for additional support if their...

  12. PneuX to prevent ventilator-associated pneumonia (MTG48)

    Evidence-based recommendations on PneuX to prevent ventilator-associated pneumonia.

  13. Danis stent for acute oesophageal variceal bleeding (MTG57)

    Evidence-based recommendations on Danis stent for acute oesophageal variceal bleeding.

  14. Cladribine for treating relapsing–remitting multiple sclerosis (TA616)

    Evidence-based recommendations on cladribine (Mavenclad) for relapsing–remitting multiple sclerosis in adults.

  15. Relugolix for treating hormone-sensitive prostate cancer (TA995)

    Evidence-based recommendations on relugolix (Orgovyx) for hormone-sensitive prostate cancer in adults.